AnHeart Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as AHT) was established in November 2018, headquartered in Hangzhou, Zhejiang Province, China, with offices in Beijing, Shanghai and New York City. AHT is dedicated to the development innovative pharmaceutical of significant improvement in human health and quality of life, with a particular focus on innovative drug for unmet clinical needs.
Founded by a team of experienced experts with extensive global clinical development and registration experience, AHT has attracted professionals with rich experience in multinational pharmaceutical companies and innovative domestic pharmaceutical companies. The business model is to in-license assets externally as well as to develop programs internally In Q1 2019, AHT successfully completed the series A round of $15 million financing, and plans to enrich our pipeline partly through collaboration with large and medium-sized biopharmaceutical companies. At present, the company is mainly engaged in the development of late clinical stage oncology drugs, particularly assets with a clear mechanism of action and convincing clinical or preclinical data support; and with a rapid registration and development pathway for unmet medical needs for patients in China and around the world.
AHT in-licensed a highly efficient ROS1/NTRK dual-target inhibitor AB-106 from Japan Daiichi Sankyo in December 2018. Two phase I clinical trials have been completed each in the United States and Japan. AB-106 showed some significant anticancer effect in some patients. AHT is about to start phase II trials of AB-106 in China and other countries in the first quarter of 2020 and hopefully will soon bring patients with a safe, effective, and relatively low cost tumor-agnostic anti-cancer drug.